Journal article · 2022 · Open access
Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314
ACS Pharmacology & Translational Science, 5(1), 20–40 · Published 5 January 2022 · DOI 10.1021/acsptsci.1c00251
In brief
“Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314” is a 2022 journal article by Merlin Bresinsky and 14 co-authors, published in ACS Pharmacology & Translational Science. OpenAlex counts 18 citations as of 22 November 2026, which puts it in the top 8% of works published in 2022 by citations. It is open access: the full text is free to read at PubMed Central.
- Citations
- 18
- Most cited in
- 2022 (5)
- Field-weighted impact
- 1.02
- References
- 52
- Authors
- 15
Abstract
Alzheimer’s disease (AD) was first described by Alois Alzheimer over 100 years ago, but there is still no overarching theory that can explain its cause in detail. There are also no effective therapies to treat either the cause or the associated symptoms of this devastating disease. A potential approach to better understand the pathogenesis of AD could be the development of selective caspase-2 (Casp2) probes, as we have shown that a Casp2-mediated cleavage product of tau (Δtau314) reversibly impairs cognitive and synaptic function in animal models of tauopathies. In this article, we map out the Casp2 binding site through the preparation and assay of a series of 35 pentapeptide inhibitors with the goal of gaining selectivity against caspase-3 (Casp3). We also employed computational docking methods to understand the key interactions in the binding pocket of Casp2 and the differences predicted for binding at Casp3. Moreover, we crystallographically characterized the binding of selected pentapeptides with Casp3. Furthermore, we engineered and expressed a series of recombinant tau mutants and investigated them in an in vitro cleavage assay. These studies resulted in simple peptidic inhibitors with nanomolar affinity, for example, AcVDV(Dab)D-CHO ( 24 ) with up to 27.7-fold selectivity against Casp3. Our findings provide a good basis for the future development of selective Casp2 probes and inhibitors that can serve as pharmacological tools in planned in vivo studies and as lead compounds for the design of bioavailable and more drug-like small molecules.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Bresinsky, M., Strasser, J. M., Vallaster, B., Liu, P., McCue, W. M., Fuller, J. L., Hubmann, A., Singh, G., Nelson, K. M., Cuellar, M. E., Wilmot, C. M., Finzel, B. C., Ashe, K. H., Walters, M. A., & Pockes, S. (2022). Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314. ACS Pharmacology & Translational Science, 5(1), 20–40. https://doi.org/10.1021/acsptsci.1c00251
MLA 9
Bresinsky, Merlin, et al. “Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314.” ACS Pharmacology & Translational Science, vol. 5, no. 1, 2022, pp. 20–40. https://doi.org/10.1021/acsptsci.1c00251.
Chicago
Bresinsky, Merlin, Jessica M. Strasser, Bernadette Vallaster, Peng Liu, William M. McCue, Jessica L. Fuller, Alexander Hubmann, et al. 2022. “Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314.” ACS Pharmacology & Translational Science 5 (1): 20–40. https://doi.org/10.1021/acsptsci.1c00251.
Harvard
Bresinsky, M. et al. (2022) ‘Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314’, ACS Pharmacology & Translational Science, 5(1), pp. 20–40. doi:10.1021/acsptsci.1c00251.
IEEE
M. Bresinsky et al., “Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314,” ACS Pharmacology & Translational Science, vol. 5, no. 1, pp. 20–40, 2022, doi: 10.1021/acsptsci.1c00251.
BibTeX
@article{bresinsky2022structure,
title = {{Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314}},
author = {Bresinsky, Merlin and Strasser, Jessica M. and Vallaster, Bernadette and Liu, Peng and McCue, William M. and Fuller, Jessica L. and Hubmann, Alexander and Singh, Gurpreet and Nelson, Kathryn M. and Cuellar, Matthew E. and Wilmot, Carrie M. and Finzel, Barry C. and Ashe, Karen H. and Walters, Michael A. and Pockes, Steffen},
journal = {ACS Pharmacology \& Translational Science},
year = {2022},
volume = {5},
number = {1},
pages = {20--40},
doi = {10.1021/acsptsci.1c00251},
url = {https://doi.org/10.1021/acsptsci.1c00251}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2022 | 5 | |
| 2023 | 4 | |
| 2024 | 2 | |
| 2025 | 2 | |
| 2026 | 5 |
Its field-weighted citation impact is 1.02: it has been cited 1.02 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- tau cleavage
- Alzheimer's disease
- crystal structure
- molecular docking
- tauopathy
- structure-based drug design
Work with this paper
Most-cited papers in Neuroscience
- The Rat Brain in Stereotaxic CoordinatesGeorge Paxinos, CHARLES R. R. WATSON · Elsevier eBooks · 1982 · 52,413 citations
- The assessment and analysis of handedness: The Edinburgh inventoryRichard Charles Oldfield · Neuropsychologia · 1971 · 36,725 citations
- EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysisArnaud Delorme A, Scott Makeig · Journal of Neuroscience Methods · 2004 · 25,302 citations
- The Ecological Approach to Visual PerceptionMarc H. Bornstein, James J. Gibson · Journal of Aesthetics and Art Criticism · 1980 · 22,977 citations
- The Psychophysics ToolboxDavid H. Brainard · Spatial Vision · 1997 · 20,208 citations
Questions about this paper
How do I cite this paper in APA style?
Bresinsky, M., Strasser, J. M., Vallaster, B., Liu, P., McCue, W. M., Fuller, J. L., Hubmann, A., Singh, G., Nelson, K. M., Cuellar, M. E., Wilmot, C. M., Finzel, B. C., Ashe, K. H., Walters, M. A., & Pockes, S. (2022). Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314. ACS Pharmacology & Translational Science, 5(1), 20–40. https://doi.org/10.1021/acsptsci.1c00251
How many times has this paper been cited?
18 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at PubMed Central: sign in and open the full text from this page.
Who wrote this paper?
Merlin Bresinsky, Jessica M. Strasser, Bernadette Vallaster, Peng Liu, William M. McCue, Jessica L. Fuller, Alexander Hubmann, Gurpreet Singh, Kathryn M. Nelson, Matthew E. Cuellar, Carrie M. Wilmot, Barry C. Finzel and 3 more.
What is the DOI of this paper?
10.1021/acsptsci.1c00251, permanently at https://doi.org/10.1021/acsptsci.1c00251. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.